UNSPSC 51433934: Lercanidipine hydrochloride

This classification denotes a calcium channel blocker with the molecular formula C36H41N3O6.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OA8TFX68PE, chemically known as 2-((3,3-diphenylpropyl)methylamino)-1,1-dimethylethyl methyl (4rs)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate monohydrochloride but more generally known as lercanidipine hydrochloride, which bears US NIH Compound Identifier 157917.

UNSPSC 51433934 Lercanidipine hydrochloride is a Commodity code that encompasses prescription medications supplied through state and local government procurement channels, particularly for emergency medical services, pharmacy benefit programs, and multistate cooperative purchasing vehicles. State and local governments buy specific pharmaceutical products under this code to support fire rescue operations, state health agency pharmacy initiatives, and cooperative purchasing agreements that aggregate demand across multiple jurisdictions. The issuing bodies include city fire departments and emergency medical services, state health and human services agencies, and multistate cooperative purchasing alliances that procure on behalf of participating state and local government members.

Recent activity centers on three distinct procurement mechanisms. The City of Tampa issued an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications for Tampa Fire Rescue, requesting 370 units of Labetalol HCI, 1,810 units of Epinephrine, 330 units of Adenosine, and 1,020 units of Diltiazem, with a one-year contract term and options to renew, estimated at $40,000 and designated as a sheltered Small Local Business Enterprise (SLBE) market with a 5 percent bid discount. The Texas Health and Human Services Commission issued a Request for Information (RFI) in April 2026 to explore direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager arrangements, seeking vendor capabilities for implementing value-based contracting models with self-insured plans. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP due March 2026 to establish multistate contracts for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers effective July 1, 2026, with evaluation weighted heavily toward price competitiveness (75 percent) and requiring compliance with cGMP and Drug Supply Chain Security Act standards. Geographic activity spans Florida, Texas, Minnesota, and Oregon through the cooperative vehicle. The Tampa and MMCAP opportunities represent the most concrete commodity-level procurement signals; the Texas RFI reflects exploratory program design rather than immediate commodity demand.